Introduction {#S0001}
============

Percutaneous coronary intervention (PCI) plays a crucial role in the management of coronary artery disease, especially in the setting of acute ST-elevation myocardial infarction (STEMI). However, even if complete revascularization is achieved, adequate reperfusion in the myocardium as demonstrated on angiography is not necessarily maintained.[@CIT0001],[@CIT0002] Previous studies showed that the prevalence of CSF/NRP in all patients who underwent PCI was 2--3.2%.[@CIT0003]--[@CIT0005] Studies also confirmed that CSF/NRP occurred in a significant proportion of patients with STEMI during emergency PCI with an incidence of 30--40%.[@CIT0006]--[@CIT0008] Increasing evidence has suggested that CSF/NRP is associated with PCI-related myocardial infarction, in-hospital mortality, and a poor prognosis.[@CIT0004],[@CIT0009],[@CIT0010]

CTO is defined as thrombolysis in myocardial infarction (TIMI) grade 0 flow with a 3-month duration documented angiographically or clinically defined.[@CIT0011] Previous studies showed that approximately 20% of patients with coronary heart disease have at least one vascular CTO lesion.[@CIT0011] Accumulating evidence has confirmed that successful revascularization can effectively improve myocardial ischemia and relieve angina,[@CIT0012] improve left ventricular function,[@CIT0013] and improve clinical outcomes[@CIT0014],[@CIT0015] in patients with CTO. However, a higher risk of CTO-PCI, longer procedure duration, and larger number of implanted stents made it different from routine interventional therapy, and the incidence of CSF/NRP and its effects on prognosis remain unclear.

This study sought to investigate the incidence of CSF/NRP in patients with CTO who underwent PCI, determine the predictors of CSF/NRP, and assess its effects on patient outcomes.

Methods {#S0002}
=======

Study Design and Patients {#S0002-S2001}
-------------------------

In this study, patients with a confirmed diagnosis of CTO were consecutively selected between January 2015 and May 2018 at our hospital. The exclusion criteria were as follows: current pregnancy; known allergy to aspirin, clopidogrel, or ticagrelor; refusal to accept interventional therapy or no stent implantation; life expectancy \<1 year; and refusal to participate in the trial. CSF/NRP was defined as TIMI grade ≤2 by two experienced cardiologists (Ai-jie Hou and Bo Luan).A total of 552 patients were enrolled in the study, including 89 with CSF/NRP and 463 with normal blood flow ([Figure 1](#F0001){ref-type="fig"}).Figure 1Study profile.**Abbreviations:** PCI, percutaneous coronary intervention; CSF, coronary slow-flow.

The radial artery was the routine access point, but the physician determined the access as needed. During the procedure, a standard dose of unfractionated heparin 100 IU/kg was used as anticoagulant therapy, and unfractionated heparin 2000 IU was added every hour. The use of glycoprotein IIb/IIIa inhibitor (GPI) was left to the physician's discretion. The study was approved by the Institutional Review Board of the People's Hospital of Liaoning Province and complied with the Declaration of Helsinki. All patients signed informed consent before participation.

Study end points {#S0002-S2002}
----------------

The primary study end point was a composite of major cardiac and cerebrovascular events (MACCEs), including cardiac death, target vessel revascularization (TVR), stent thrombosis, nonfatal myocardial infarction (MI), PCI-associated MI (during the hospitalization period), and nonfatal stroke within 1 year of follow-up. MI was defined as the presence of pathological Q waves in at least two consecutive leads, or without a pathological Q wave, the markers of myocardial injury increased to more than twice the upper limit of normal but was not related to PCI or bypass.[@CIT0016] PCI-related MI was defined as an elevated cardiac troponin T (cTn) value to more than five times the 99^th^ percentile of cTn level in patients with normal baseline values.[@CIT0016]

Statistical Analysis {#S0002-S2003}
--------------------

The Statistical Package for the Social Sciences for Windows version 20 (IBM SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. Normally distributed continuous data are described as mean±standard deviation, while non-normally distributed data are shown as median (range). Categorical variables are shown as number and percentage. To compare continuous variables, Student's *t* test or the Mann--Whitney *U*-test was used. To compare categorical variables, the chi-square test and Fisher's exact test were used in the case of sparse data. Kaplan-Meier graphs were used to assess survival without MACCEs. All tests were two-sided, and p values \<0.05 were considered significant.

Results {#S0003}
=======

A total of 552 CTO patients who underwent PCI were included in this study ([Figure 1](#F0001){ref-type="fig"}). CSF/NRP occurred in 16.1% of the patients. The patients with CSF/NRP had higher incidences of diabetes mellitus (53.9% vs 36.3%, p=0.002) and hypertension (50.6% vs 37.1%, p=0.018) and a lower rate of retrograde filling of grade \>2 (34.8% vs 47.1%, p=0.036; [Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}). The patients with CSF/NRP had a higher neutrophil ratio (55.6±19.4 vs 52.4±18.3, p=0.038) and higher levels of low-density lipoprotein (LDL; 3.0±0.8 vs 2.8±0.6, p=0.029), FG (8.3± 1.3 vs 6.8 ±1.1, p=0.005), uric acid (332.6±82.9 vs 308.2±62.8, p=0.045), and high-sensitivity C-reactive protein (Hs-CRP; 9.8±4.8 vs 7.3±3.9, p=0.036; [Table 2](#T0002){ref-type="table"}).Table 1Clinical Characteristics of the Study PopulationVariableCSF/NRP Group (n=89)Non- CSF/NRP Group (n=463)PvalueAge(years)64.5±7.965.2±8.10.854Sex (female), n(%)39(43.8%)204(44.1%)1Body mass index (kg/m^2^)22.8±3.523.1±3.70.628Diabetes mellitus, n(%)48(53.9%)168(36.3%)**0.002**Hypertension, n(%)45(50.6%)172(37.1%)**0.018**Current smoker, n(%)32(36.0%)142(30.7%)0.383Previous MI, n(%)41(46.1%)212(45.8%)1Previous ischemic CVA, n(%)9(10.1%)41(8.9%)0.840LVEF(%)40.8±6.240.2±6.40.328NYHA 2--3 on admission, n(%)62(69.7%)362(78.2%)0.099eGFR, mL/min/1.73 mm^2^60.5±22.861.1±23.60.462ACEIs/ARBs, n(%)42(47.2%)231(49.9%)0.646Beta-blockers, n(%)40(44.9%)229(49.5%)0.488Statin, n(%)86(96.6%)454(98.1%)0.421PPI, n(%)84(94.4%)449(97.0%)0.210WBC count (10^9^/L)6.8±1.96.7±1.70.764MPV(fL)10.1±0.810.4±0.90.195Neutrophil ratio (%)55.6±19.452.4±18.3**0.038**PDW (%)11.9±1.811.2±1.50.214HDL-C (mmol/L)1.2±0.41.1±0.30.29LDL-C (mmol/L)3.0±0.82.8±0.6**0.029**TG (mmol/L)1.6±0.91.5±0.80.682TC (mmol/L)4.6±0.94.4±0.80.692FG (mmol/L)8.3± 1.36.8±1.1**0.005**Creatinine (mg/dL)58.4±11.957.9±11.60.328UA (mmol/L)332.6±82.9308.2±62.8**0.045**Hs-CRP (mmol/L)9.8±4.87.3±3.9**0.037**[^1] Table 2Procedure-Related Characteristics of the Studied PatientsVariablesCSF/NRP Group (n=89)Non- CSF/NRP Group (n=463)PvalueProcedural accessRadial32(36.0%)146(31.5%)0.242Femoral22(24.7%)118(25.5%)0.896Radial and femoral35(39.3%)199(43.0%)0.559Total amount of contrast(mL)245.8±123.6239.4±119.70.681Total time of procedure (min)118.4±56.7116.5±55.80.395LAD occlusion, n (%)23(25.8%)126(27.2%)0.797LCX occlusion, n (%)22(24.7%)118(25.5%)0.896RCA occlusion, n (%)47(52.8%)225(48.6%)0.489Occlusion lesion length, mm56.8±24.757.4±23.60.628Retrograde filling \> grade 231(34.8%)218(47.1%)**0.036**Reverse wire technique38(42.7%)186(40.2%)0.724IABP, n(%)6(6.7%)36(7.8%)0.813IVUS, n(%)17(19.1%)102(22.0%)0.577Number of stents per patient2.6±1.82.7±1.90.684Stent length (mean, mm)62.8±22.563.4±24.30.892Glycoprotein IIb/IIIa receptor inhibitor, n(%)42(47.2%)252(54.4%)0.246LMWH (%)29(32.6%)135(29.2%)0.528[^2]

Age, female sex, smoking, body mass index, diabetes mellitus, hypertension, mean platelet volume (MPV), neutrophil ratio, platelet distribution width (PDW), LDL cholesterol (LDL-C), fasting glucose (FG), uric acid, Hs-CRP, retrograde filling of grade \>2, and GPI were analyzed in univariate analysis. Diabetes mellitus, hypertension, MPV, neutrophil ratio, PDW, LDL-C, FG, Hs-CRP, and retrograde filling of grade \>2 were included in the multivariate logistic regression analysis. Diabetes mellitus (odds ratio \[OR\], 1.962; 95% confidence interval \[CI\], 1.198--2.721; p=0.042), MPV(OR, 1.284; 95% CI, 1.108--1.895, p = 0.046), LDL-C (OR, 1.383; 95% CI, 1.105--2.491, p = 0.036), FG(OR, 2.095; 95% CI, 1.495--2.899, p = 0.018), Hs-CRP (OR, 2.218; 95% CI, 1.556--3.519; p = 0.029), and retrograde filling of grade \>2 (OR, 0.822; 95% CI, 0.622--0.907; p = 0.037) were independent predictors of CSF/NRP in patients with CTO treated with PCI ([Table 3](#T0003){ref-type="table"}).Table 3Univariate and Stepwise Multivariate Logistic Regression Analysis of Risk Factors of CSF/NRPUnivariate AnalysisMultivariate AnalysisOR95% CIP valueOR95% CIP valueAge1.0000.729--1.2130.782------Female sex0.8920.658--1.8690.692------Current smoking1.1240.732--1.6850.358------Body mass index1.0970.912--2.2890.529------Diabetes mellitus1.8951.271--2.826**0.035**1.9621.198--2.721**0.042**Hypertension1.6841.118--1.959**0.029**1.3751.122--1.8990.182PDW1.3211.09--1.59**0.029**1.2041.181--1.6880.089Neutrophil ratio1.2941.112--1.985**0.034**1.1821.091--1.9790.132MPV1.3071.092--1.995**0.026**1.2841.108--1.895**0.046**LDL-C1.4221.166--2.521**0.019**1.3831.105--2.491**0.036**FG2.1141.562--3.095**0.028**2.0951.495--2.899**0.018**UA1.1860.897--1.5680.624------Hs-CRP2.3231.629--3.592**0.012**2.2181.556--3.519**0.029**Retrograde filling \> grade 20.7820.556--0.925**0.025**0.8220.622--0.907**0.037**GPI1.1950.893--1.6880.329------[^3]

During the hospitalization period, the incidence of PCI-related MI was significantly higher in the CSF/NRP group than in the non-CSF/NRP group (32.6% vs 14.9%, *p*\<0.001), and the incidence of MACCEs was also significantly higher in the CSF/NRP group than in the non-CSF/NRP group (37.1% vs 18.6%, *p*\<0.001). At 1-year follow-up, the incidences of TVR (22.0% vs 5.8%, *p*\<0.001) and MACCE (47.2% vs 21.4%, *p*\<0.001) were significantly higher in the CSF/NRP group than in the non-CSF/NRP group ([Table 4](#T0004){ref-type="table"}). Kaplan-Meier analysis revealed that the cumulative MACCE-free survival was significantly lower in the CSF/NRP group than in the non-CSF/NRP group (*p*\<0.0001; [Figure 2](#F0002){ref-type="fig"}).Table 4MACCE During Hospital Stay and at 12-Monthfollow-UpVariableCSF/NRP Group (n=89)Non- CSF/NRP Group (n=463)PvalueMACCE during hospitalizationCardiogenic death, n(%)1(1.1%)4(0.9%)1AMI, n(%)1(1.1%)6(1.3%)1PCI-relatedMI, n(%)29(32.6%)69(14.9%)**\<0.001**Stent thrombosis, n(%)1(1.1%)7(1.5%)1Stroke, n(%)02(0.4%)1TVR, n(%)3(3.4%)13(2.8%)0.731Overall MACCE, n(%)33(37.1%)86(18.6%)**\<0.001**MACCE at12-month follow-upCardiogenic death, n(%)1(1.1%)6(1.3%)1AMI, n(%)2(2.2%)16(3.5%)0.751Stent thrombosis, n(%)6(6.7%)22(4.8%)0.430Stroke, n(%)1(1.1%)3(0.6%)0.506TVR, n(%)11(22.0%)27(5.8%)**\<0.001**Overall MACCE, n(%)42(47.2%)99(21.4%)**\<0.001**[^4] Figure 2Cumulative MACCE-free survival.

Discussion {#S0004}
==========

This study was the first to investigate the incidence, predictive factors, and prognosis of CSF/NRP inpatients with CTO who successfully underwent PCI. The study confirmed that16.1% of patients with CTO who underwent PCI developed CSF, which had a significantly lower cumulative MACCE-free survival rate. Diabetes mellitus; higher MPV and levels of LDL-C, FG, and Hs-CRP; and a lower retrograde filling level (grade \>2) were independent predictors of CSF/NRP in patients with CTO who underwent PCI. Thus, these factors can be used for risk stratification.

The etiology of CSF/NRP is complex and still not fully understood. Its possible mechanisms include endothelial dysfunction, microvascular ischemia and edema, embolization, and reperfusion injury.[@CIT0017] Currently, the incidence of CSF/NRP varies widely among different study populations. Most of these studies were in STEMI patients. Some recent studies demonstrated that the proportion of NRP in all PCI patients was2--3.2%.[@CIT0003]--[@CIT0005] Studies also confirmed that CSF/NRP occurred at a prevalence of 30--40% in STEMI patients during emergency PCI.[@CIT0006]--[@CIT0008] The present study showed that the incidence of CSF/NRP in such patients was as high as 16.1%. We speculated that the guide wire may penetrate the proximal or distal fibrous cap during antegrade interventional therapy or the retrograde wire technique, causing the release of lipids from atherosclerotic plaques that may lead to the occlusion of distal blood vessels, especially micro vessels.

Although many researchers have proposed several predictors of CSF/NRP,[@CIT0018] their predictive value in different study populations requires further investigation. Studies have confirmed that \>50% of patients with STEMI have abnormal glucose metabolism. Although early revascularization can achieve significant clinical results, patients with abnormal glucose metabolism have poorer microvascular perfusion and a higher risk of developing CSF/NRP.[@CIT0019] The present study also found that diabetes mellitus and a high fasting blood glucose level are independent predictors of CSF/NRP as shown in previous studies. The present study demonstrated that a high LDL-C level is associated with CSF/NRP. Previous studies confirmed that hypercholesterolemia is associated with endothelial dysfunction because it reduces the bioavailability of vascular nitric oxide.[@CIT0020] Pretreatment with statins effectively prevents CSF/NRP,[@CIT0021] reduces the incidence of postoperative MI,[@CIT0022] and improves myocardial perfusion after PCI.[@CIT0023] These findings also indirectly confirm that hyperlipidemia is involved in the pathogenesis of CSF/NRP.

Studies have shown that a higher inflammation status plays an important role in the development of CSF/NRP during emergency PCI for STEMI.[@CIT0024] Oduncuet al[@CIT0025] showed that patients with NRP have a higher baseline Hs-CRP level. The independent relationship between Hs-CRP and NRP development, which was discovered in this study, has also been reported previously.[@CIT0026] The present study confirmed that MPV was significantly elevated in the CSF/NRP group and is an independent predictor of CSF/NRP. We suggest that MPV is an indicator of platelet activation that plays an important role in the pathophysiology of cardiovascular disease; previous studies also confirmed its association with CSF/NRP.[@CIT0018] We also found that patients with better collateral circulation had a lower incidence of CSF/NRP, presumably because the collateral circulation provides better myocardial perfusion to occluded vessels and its endothelial and microvascular functions are relatively less damaged; thus, the incidence of CSF/NRP is lower because reperfusion-related damage is less severe.

CSF/NRP is clinically important, as increasing evidence has suggested that it is associated with PCI-related MI, in-hospital mortality, and poor prognosis.[@CIT0004],[@CIT0009],[@CIT0010] In addition, Butler et al reported that transient CSF/NRP is even more common than persistent CSF/NRP and results in significantly increased 30-day morbidity and mortality rates.[@CIT0027] Our study found that CTO-PCI patients with CSF/NRPs had significantly increased incidences of perioperative MI, MACCEs during hospitalization and the 1-year follow-up period, and TVRat1-year follow-up. Their MACCE-free survival rate was significantly lower than that of non-CSF/NRP patients.

The CSF/NRP condition of CTO-PCI patients warrants additional attention due to its unique pathophysiology and complex interventional procedures. We recommend that these conditions be identified separately from acute MI. As this was a small-sample single-center study, some bias exists. In the future, a large-sample multicenter prospective randomized controlled trial is needed to validate our conclusions.

Conclusion {#S0005}
==========

Of the patients with CTO who underwent PCI, 16.1% developed CSF/NRP and had a significantly lower cumulative MACCE-free survival rate. Diabetes mellitus; higher MPV, LDL-C, FG, and Hs-CRP levels; and a lower incidence of retrograde filling grade \>2 were independent predictors of CSF/NRP in CTO patients who underwent PCI. Thus, these factors can be used for risk stratification.
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CSF, coronary slow-flow; NRP, no-reflow phenomenon; TIMI, thrombolysis in myocardial infarction; CTO, coronary chronic total occlusion; PCI, percutaneous coronary intervention; MACCE, major adverse cardiac and cerebral events; TVR, target vessel revascularization; GPI, glycoprotein IIb/IIIa inhibitor.
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[^1]: **Note:** Bold values are statistically significant (*p*\< 0.05).

    **Abbreviations:** MI, myocardial infarction; CVA, cerebrovascular accident; GI, gastrointestinal; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; PPI, proton pump inhibitor; MPV,mean platelet volume; PDW, platelet distribution width; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TC, total cholesterol; FG, fasting glucose; UA, uric acid; Hs-CRP,high-sensitivity C-reactive protein.

[^2]: **Abbreviations:** LAD, left anterior descending artery; LCX, left circumflex coronary artery; RCA, right coronary artery; IABP, intra-aortic balloon pump; IVUS, intravascular ultrasonography; TIMI, thrombolysis in myocardial infarction; LMWH, low-molecular-weight heparin.

[^3]: **Note:** Bold values are statistically significant (*p*\< 0.05).

    **Abbreviations:** MPV, mean platelet volume; PDW, platelet distribution width; LDL, low-density lipoprotein; FG, fasting glucose; UA, uric acid; Hs-CRP, high-sensitivity C-reactive protein; GPI,glycoprotein IIb/IIIa receptor inhibitor.

[^4]: **Note:** Bold values are statistically significant (*p*\< 0.05).

    **Abbreviations:** MACCE, major adverse cardiac and cerebral events; PCI, percutaneous coronary intervention; TVR, target vessel revascularization; AMI, acute myocardial infarction.
